Scientist-inventors from ORNL will present seven new technologies during the Technology Innovation Showcase on Friday, July 14, from 8 a.m.–4 p.m. at the Joint Institute for Computational Sciences on ORNL’s campus.
ORNL’s electromagnetic isotope separator, or EMIS, made history in 2018 when it produced 500 milligrams of the rare isotope ruthenium-96, unavailable anywhere else in the world.
Three scientists from the Department of Energy’s Oak Ridge National Laboratory have been elected fellows of the American Association for the Advancement of Science, or AAAS.
Laboratory Director Thomas Zacharia presented five Director’s Awards during Saturday night's annual Awards Night event hosted by UT-Battelle, which manages ORNL for the Department of Energy.
Two years after ORNL provided a model of nearly every building in America, commercial partners are using the tool for tasks ranging from designing energy-efficient buildings and cities to linking energy efficiency to real estate value and risk.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
ORNL, TVA and TNECD were recognized by the Federal Laboratory Consortium for their impactful partnership that resulted in a record $2.3 billion investment by Ultium Cells, a General Motors and LG Energy Solution joint venture, to build a battery cell manufacturing plant in Spring Hill, Tennessee.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
In experiment after experiment, the synthetic radioisotope actinium-225 has shown promise for targeting and attacking certain types of cancer cells.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.